Sectors
CADL
Candel Therapeutics, Inc.
13.07
2 x 7.49
2 x 13.51
bid
ask
+
0.00
0.00%
2 @ 07:30 PM
13.07 +0.00 (0.00%)
| Ytd | 131.33% | |
| 1y | 125.73% |
12.63
day range
13.22
4.35
52 week range
14.00
| Open | 13.02 | Prev Close | 13.07 | Low | 12.63 | High | 13.22 | Mkt Cap | 1.00B |
| Vol | 895.01K | Avg Vol | 1.62M | EPS | -1.47 | P/E | N/A | Forward P/E | -22.00 |
| Beta | -0.50 | Short Ratio | 10.24 | Inst. Own | 66.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 10.58 | 200-d Avg | 7.19 | 1yr Est | 21.00 |
| Income Statement | |||
| Operating Expenses | 26.75M | ||
| Research and Development Expense | 19.80M | ||
| Selling, General and Administrative Expense | 6.95M | ||
| Operating Income | -26.75M | ||
| Interest Expense | 1.58M | ||
| Net Income | -38.90M | ||
| Net Income Common Stock | -38.90M | ||
| Net Income Common Stock (USD) | -38.90M | ||
| Consolidated Income | -38.90M | ||
| Earnings per Basic Share | -0.52 | ||
| Earnings per Basic Share (USD) | -0.52 | ||
| Earnings per Diluted Share | -0.52 | ||
| Earning Before Interest & Taxes (EBIT) | -37.33M | ||
| Earning Before Interest & Taxes (USD) | -37.33M | ||
| Weighted Average Shares | 74.13M | ||
| Weighted Average Shares Diluted | 74.13M | ||
| Balance Sheet | |||
| Cash and Equivalents | 201.98M | ||
| Cash and Equivalents (USD) | 201.98M | ||
| Current Assets | 204.16M | ||
| Property, Plant & Equipment Net | 3.48M | ||
| Total Assets | 208.15M | ||
| Debt Current | 461.00K | ||
| Total Debt | 49.52M | ||
| Current Liabilities | 12.69M | ||
| Debt Non-Current | 49.06M | ||
| Total Liabilities | 82.02M | ||
| Accumulated Retained Earnings (Deficit) | -278.15M | ||
| Shareholders Equity | 126.13M | ||
| Shareholders Equity (USD) | 126.13M | ||
| Assets Non-Current | 3.99M | ||
| Total Debt (USD) | 49.52M | ||
| Deferred Revenue | 45.00K | ||
| Liabilities Non-Current | 69.33M | ||
| Trade and Non-Trade Payables | 5.15M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 265.00K | ||
| Net Cash Flow from Financing | 23.98M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 6.73M | ||
| Capital Expenditure | -69.00K | ||
| Issuance (Purchase) of Equity Shares | 23.98M | ||
| Net Cash Flow from Investing | -69.00K | ||
| Net Cash Flow from Operations | -17.18M | ||
| Share Based Compensation | 2.86M | ||